|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.35 USD | -0.30% |
|
-2.13% | -20.26% |
| Apr. 13 | Jefferies Initiates Veracyte at Buy With $45 Price Target | MT |
| Mar. 16 | Veracyte names Kevin Haas as chief development and technology officer | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Diagnostics & Testing
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.66B | |||||
| 2.27B | - | - | - | - | - |
| 2.25B | - | ||||
| 1.56B | - | ||||
| 1.09B | - | - | |||
| 1.04B | - | - | - | - | - |
- Stock Market
- Equities
- VCYT Stock
- Charts Veracyte, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
